Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

被引：0
|
作者：
Chen, X. [1 ]
Zhang, H. [1 ]
Li, Y. [1 ]
Liu, L. [1 ]
Qu, X. [1 ]
机构：
[1] Guangzhou Univ Tradit Chinese, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Small Cell Lung Cancer; Immune checkpoint inhibitors; Efficacy and Safety;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP14.01-00
引用
收藏
页码：S527 / S527
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Tislelizumab Plus Anlotinib and 2-Cycle Irinotecan as Second-Line Treatment for ES-mall Cell Lung Cancer(ESTAIL)
    Chen, X.
    Zhang, H.
    Li, W.
    Qu, Y.
    Qu, X.
    Zhou, R.
    Hong, H.
    Zhu, Y.
    Chai, X.
    Liu, L.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S126 - S127
  • [2] Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study
    Du, Yang
    Liu, Xiao-Yan
    Si, Xiao-Yan
    Zhang, Xiao-Tong
    Zhou, Jing-Ya
    Wang, Yi
    Chen, Min-Jiang
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07)
  • [3] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
  • [4] Irinotecan as a Second-line Monotherapy for Small Cell Lung Cancer
    Sevinc, Alper
    Kalender, Mehmet Emin
    Altinbas, Mustafa
    Ozkan, Metin
    Dikilitas, Mustafa
    Camci, Celalettin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (04) : 1055 - 1059
  • [5] RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
    Paz-Ares, L.
    Spigel, D. R.
    Chen, Y.
    Jove, M.
    Juan-Vidal, O.
    Rich, P.
    Hayes, T.
    Gutierrez Calderon, V.
    Caro, R. B.
    Navarro, A.
    Dowlati, A.
    Zhang, B.
    Moore, Y.
    Yao, X.
    Kokhreidze, J.
    Ponce, S.
    Bunn, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S216 - S216
  • [6] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer
    Fu, Jun
    Fang, Sanyou
    Wen, Yin
    Wang, Yanbing
    Yin, Xin
    Wang, Daofeng
    JOURNAL OF BUON, 2020, 25 (04): : 1707 - 1713
  • [8] Second-line treatment of small cell lung cancer
    Schmittel, A.
    Sebastian, M.
    Niederle, N.
    ONKOLOGE, 2013, 19 (11): : 940 - +
  • [9] Efficacy and safety of anlotinib combined with vinorelbine as second-line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort
    Li, Yonghong
    Li, Wei
    Liu, Yirui
    Peng, Yi
    Tang, Jing
    Li, Xiaobing
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (02)
  • [10] A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensivedisease small cell lung cancer
    Wang, Z.
    Han, X.
    Guo, J.
    Li, L.
    Huang, Y.
    Ma, L.
    Zhao, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
12345